Indications:
Used for duodenal ulcers with bleeding that are not suitable for oral therapy.
Dosage:
Intravenous drip: usually 30mg for adults once, dissolved in 100ml of 0.9% sodium chloride injection, twice a day, the recommended intravenous drip time is 30 minutes, and the course of treatment should not exceed 7 days.
Note when using:
(1) This product should be equipped with a filter with a pore size of 1.2μm when used intravenously to remove the sediment that may be produced during the infusion process. These deposits may cause embolism of small blood vessels and have serious consequences.
(2) In cases of high risk such as spouting or gushing massive bleeding, vascular exposure, etc., endoscope hemostasis measures should be used first.
(3) This product is only used for intravenous drip. It should be used as soon as possible after dissolution, do not store. Avoid mixing with liquids other than 0.9% sodium chloride injection and other drugs intravenously.
(4) If the hemostatic effect is achieved within the first 3 days of treatment with this product, oral medication should be used instead of unlimited intravenous administration
Adverse reactions:
In domestic clinical studies, this product was injected intravenously at 30mg twice a day for 5 days. Among 127 subjects, 4 cases (3.64%) had adverse reactions, mainly leukopenia (1.82%), slightly elevated transaminase (0.91%) and skin rash (0.91%). Leukopenia patients will be rechecked after a week, and transaminase will be slightly elevated after 10 days.
After being marketed abroad, more than 1,000 patients have good tolerance after using Lansoprazole for injection. In 4 clinical trials in the United States, 161 patients used lansoprazole for injection, and more than 1% of the adverse reactions were nausea (1.3%), headache (1%), pain at the injection site (1%); less than 1% The adverse reactions include abdominal pain, diarrhea, indigestion, vomiting, dizziness, paresthesia, abnormal taste, skin rash and vasodilation. No adverse reactions different from oral administration were seen.
According to the clinical research data of 221 subjects in Japan using Lansoprazole for injection, 31 cases (14.0%) had abnormal clinical laboratory test values, mainly due to elevated ALT (6.2%) and elevated AST (5.7%) , LDH increased (2.0%), γ-GTP increased (1.5%) and other abnormal changes in inspection values.
The following adverse reactions were seen in oral lansoprazole, but intravenous injection may also occur:
1. Close observation should be made during treatment. If the following serious adverse reactions occur, medication and treatment should be stopped in time.
(1) Allergic reactions (general rash, facial swelling, dyspnea, etc.) (<0.1%), or even shock (<0.1%);
(2) Pancytopenia and agranulocytosis, hemolysis (<0.1%), as well as neutropenia, thrombocytopenia, and anemia (0.1~<5%);
(3) Accompanied by jaundice, AST and ALT elevated and other severe liver damage (<0.1%);
(4) Toxic epidermal necrolysis (Lyell syndrome), skin mucosal eye syndrome (stevens-Johnson syndrome) (<0.1%);
(5) Interstitial pneumonia (<0.1%), fever, tender cough, dyspnea, abnormal lung breath sounds (crepitus), etc., should quickly stop medication, perform chest x-ray examination, and give adrenal cortex hormones Wait for proper treatment.
2. Other adverse reactions; discontinue the medication when the following adverse reactions occur, and take appropriate treatment if necessary.
Taboo:
1. Patients who are allergic to lansoprazole and any of the ingredients in the prescription are prohibited from using this product.
2. Patients who are using atazanavir sulfate are prohibited from using this product.
Precautions:
1. Use medication with caution in the following patients:
(1) Patients with a previous history of drug allergy;
(2) Patients with liver injury (due to delayed metabolism and excretion of the drug);
2. The treatment of this product will cover up the symptoms of gastrointestinal tumors, and the medicine should be used after malignant tumors are excluded.
3. Closely observe the condition during treatment with this product, and switch to other therapies when the treatment fails.
4. There is no medication experience for this product for more than 7 days.
5. Omeprazole, a proton pump inhibitor of the same kind, has been reported to cause visual damage abroad, but this product is not yet clear.
Audited Supplier 
Audited Supplier 
){kind=link}
){kind=link}